Find all the latest news from Frontier Science Scotland below

choose a category:

HERA

HERA

The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>

read more
OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more

Let's work together

Simply fill in this quick form and we’ll be back in touch within the next two working days. Alternatively, you can call us during usual business hours or send us an email.

9 + 13 =